ANGO (AngioDynamics) Cyclically Adjusted Revenue per Share: $9.08 (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ANGO AngioDynamics Inc ANGO
59 GF Score
Price $15.82
GF Value $9.57
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is AngioDynamics Cyclically Adjusted Revenue per Share?

AngioDynamics ANGO -1.56% 59 Cyclically Adjusted Revenue per Share is $9.08 as of May. 2026. GuruFocus rates ANGO with a GF Score™ of 59/100 and a GF Value™ of $9.57 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

AngioDynamics's adjusted revenue per share for the three months ended in May. 2026 was $2.077. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $9.08 for the trailing ten years ended in May. 2026.

During the past 12 months, AngioDynamics's average Cyclically Adjusted Revenue Growth Rate was -2.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -2.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -1.20% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 0.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of AngioDynamics was 5.20% per year. The lowest was -2.90% per year. And the median was 1.20% per year.

As of today (2026-08-21), AngioDynamics's current stock price is $15.815. AngioDynamics's Cyclically Adjusted Revenue per Share for the quarter that ended in May. 2026 was $9.08. AngioDynamics's Cyclically Adjusted PS Ratio of today is 1.74.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AngioDynamics was 3.26. The lowest was 0.55. And the median was 1.63.


AngioDynamics  (NAS:ANGO) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AngioDynamics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=15.815/9.08
=1.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AngioDynamics was 3.26. The lowest was 0.55. And the median was 1.63.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


AngioDynamics Cyclically Adjusted Revenue per Share Related Terms


AngioDynamics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for AngioDynamics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AngioDynamics Cyclically Adjusted Revenue per Share Chart

AngioDynamics Annual Data
Trend May17 May18 May19 May20 May21 May22 May23 May24 May25 May26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.93 9.91 9.66 9.27 9.08

AngioDynamics Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.27 9.21 9.06 9.00 9.08

ANGO vs NNNN, OSUR, SMTI: Cyclically Adjusted Revenue per Share Comparison

For the Medical Instruments & Supplies subindustry, AngioDynamics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AngioDynamics Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AngioDynamics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AngioDynamics's Cyclically Adjusted PS Ratio falls into.


ANGO
59GF Score
AngioDynamics Inc ANGO
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AngioDynamics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AngioDynamics's adjusted Revenue per Share data for the three months ended in May. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of May. 2026 (Change)*Current CPI (May. 2026)
=2.077/335.1230*335.1230
=2.077

Current CPI (May. 2026) = 335.1230.

AngioDynamics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201608 2.401 240.849 3.341
201611 2.397 241.353 3.328
201702 2.306 243.603 3.172
201705 0.192 244.733 0.263
201708 2.313 245.519 3.157
201711 2.319 246.669 3.151
201802 2.239 248.991 3.014
201805 0.153 251.588 0.204
201808 1.713 252.146 2.277
201811 1.866 252.038 2.481
201902 1.746 252.776 2.315
201905 1.893 256.092 2.477
201908 1.748 256.558 2.283
201911 1.843 257.208 2.401
202002 1.836 258.678 2.379
202005 1.532 256.394 2.002
202008 1.840 259.918 2.372
202011 1.899 260.229 2.446
202102 1.856 263.014 2.365
202105 1.994 269.195 2.482
202108 1.987 273.567 2.434
202111 2.004 277.948 2.416
202202 1.892 283.716 2.235
202205 2.222 292.296 2.548
202208 2.075 296.171 2.348
202211 2.163 297.711 2.435
202302 2.043 300.840 2.276
202305 2.299 304.127 2.533
202308 1.969 307.026 2.149
202311 1.966 307.051 2.146
202402 1.869 310.326 2.018
202405 1.756 314.069 1.874
202408 1.660 314.796 1.767
202411 1.780 315.493 1.891
202502 1.763 319.082 1.852
202505 1.956 321.465 2.039
202508 1.839 323.976 1.902
202511 1.912 324.122 1.977
202602 1.885 326.785 1.933
202605 2.077 335.123 2.077

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $9.08 mean?
AngioDynamics (ANGO) has a Cyclically Adjusted Revenue per Share of $9.08 as of May. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on AngioDynamics and its competitors.
Is AngioDynamics' Cyclically Adjusted Revenue per Share too high?
AngioDynamics' current Cyclically Adjusted Revenue per Share is $9.08. Overall, AngioDynamics has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AngioDynamics' Cyclically Adjusted Revenue per Share compare to NNNN and OSUR?
AngioDynamics' Cyclically Adjusted Revenue per Share of $9.08 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on AngioDynamics and its competitors. AngioDynamics's current Cyclically Adjusted Revenue per Share is $9.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AngioDynamics stock overvalued right now?
Based on GuruFocus' analysis, AngioDynamics (ANGO) is currently considered Significantly Overvalued. The stock's GF Value™ is $9.57, compared to a current price of $15.82 — trading 65.3% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is $9.08. AngioDynamics' overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For AngioDynamics (ANGO), the current Cyclically Adjusted Revenue per Share is $9.08 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AngioDynamics (ANGO) Overvalued in 2026?

Based on GuruFocus' analysis, AngioDynamics stock appears to be overvalued. The current stock price of $15.82 is trading 65.3% above its estimated GF Value™ of $9.57. GuruFocus considers AngioDynamics to be Significantly Overvalued.

Key valuation signals for ANGO:

  • Cyclically Adjusted Revenue per Share: $9.08
  • GF Value™: $9.57 vs. price of $15.82 (65.3% above fair value)
  • GF Score™: 59/100 with 7 warning signs

No single metric tells the full story. See the ANGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AngioDynamics Business Description

Other Exchanges UG2:GermanyUG2:Germany
Address 14 Plaza Drive, Latham, NY, USA, 12110
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
59GF Score

Get the complete analysis for ANGO

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.82
Price
$9.57
GF Value